Rectifypharma
Founded 2020 · 3 known investors
Rectify develops Positive Functional Modulators (PFMs), a class of oral small-molecule therapies designed to correct dysfunction in membrane proteins such as ABC transporters. Its drug pipeline targets serious diseases including primary sclerosing cholangitis, other hepatobiliary conditions, and cardio-renal-metabolic disorders like chronic kidney disease and vascular calcification.
BiotechDeep Tech
Investors · 3
Founder mafia
3 people who came through Rectifypharma went on to found or lead other companies.
Frequently asked questions
- What does Rectifypharma do?
- Rectify develops Positive Functional Modulators (PFMs), a class of oral small-molecule therapies designed to correct dysfunction in membrane proteins such as ABC transporters. Its drug pipeline targets serious diseases including primary sclerosing cholangitis, other hepatobiliary conditions, and cardio-renal-metabolic disorders like chronic kidney disease and vascular calcification.
- Who are Rectifypharma's investors?
- Rectifypharma's investors include Atlas Venture, DC Investment Partners, Longwood Fund.